Thursday, October 8, 2026 --:--:-- ET
New York 62°F Partly cloudy Los Angeles 78°F Sunny Chicago 55°F Windy
Subscribe
U.S. Edition Est. 2026 Oct. 8, 2026

US News America

Independent reporting for a changing America

Breaking
Predators Rally From 2-0 Down to Beat Canadiens 5-2 on O’Reilly’s Late Power-Play Goal Hurricane Isaias Reaches Category 2 at 100 MPH as Evacuations Are Ordered Along the Northern Gulf Coast U.S. Container Imports Hit September Record at 2.55 Million TEUs, Descartes Says Federal Judge Orders Return of Phoenix Man Deported to Equatorial Guinea, Finding Removal Unlawful FDA Approves Atezolizumab With Chemotherapy for Stage III Mismatch Repair Deficient Colon Cancer
Health

FDA Approves Atezolizumab With Chemotherapy for Stage III Mismatch Repair Deficient Colon Cancer

The FDA on Oct. 8 approved atezolizumab (Tecentriq) with fluoropyrimidine and oxaliplatin chemotherapy as adjuvant treatment for Stage III mismatch repair deficient colon cancer, based on the ATOMIC trial.

By admin Oct. 8, 2026 · 8:53 PM ET 1 min read

Empty infusion treatment chair beside an IV stand in a bright hospital room with large windows

The Food and Drug Administration on Oct. 8 approved atezolizumab (Tecentriq, Genentech) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of Stage III mismatch repair deficient (dMMR) colon cancer, the agency said. The approval covers adult and pediatric patients two years of age and older.

The FDA also approved the related formulation atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech) in the same chemotherapy combination for patients 12 years and older who weigh at least 40 kilograms, according to the agency.

Trial showed improved disease-free survival

The decision was based on the ATOMIC trial (ML39057, NCT02912559), a randomized, open-label study of 711 adults and one pediatric patient whose Stage III dMMR colon tumors had been fully removed, the FDA said. Patients received either the atezolizumab combination followed by atezolizumab alone, or chemotherapy alone.

The combination improved disease-free survival, with a hazard ratio of 0.50 (95% CI: 0.35, 0.73; p-value 0.0001), according to the FDA. Median disease-free survival had not been reached in either group at the time of the analysis. The agency said the prescribing information carries warnings for immune-mediated adverse reactions, infusion-related reactions and embryo-fetal toxicity.

Reporting based on coverage by the U.S. Food and Drug Administration.

Related Stories